Axon Enterprise, Inc $AXON Shares Bought by National Pension Service

National Pension Service raised its stake in Axon Enterprise, Inc (NASDAQ:AXON) by 1.2% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 195,766 shares of the biotechnology company’s stock after buying an additional 2,231 shares during the period. National Pension Service owned approximately 0.25% of Axon Enterprise worth $140,490,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Stone House Investment Management LLC purchased a new stake in Axon Enterprise during the third quarter worth $29,000. Hemington Wealth Management raised its stake in shares of Axon Enterprise by 70.8% during the 2nd quarter. Hemington Wealth Management now owns 41 shares of the biotechnology company’s stock worth $33,000 after buying an additional 17 shares during the last quarter. Whipplewood Advisors LLC boosted its position in shares of Axon Enterprise by 192.9% in the 2nd quarter. Whipplewood Advisors LLC now owns 41 shares of the biotechnology company’s stock worth $34,000 after buying an additional 27 shares in the last quarter. Root Financial Partners LLC acquired a new stake in Axon Enterprise in the 3rd quarter valued at about $34,000. Finally, Darwin Wealth Management LLC purchased a new position in Axon Enterprise during the 2nd quarter valued at about $37,000. Hedge funds and other institutional investors own 79.08% of the company’s stock.

Insider Activity

In other news, insider Jeffrey C. Kunins sold 1,797 shares of the stock in a transaction on Tuesday, December 2nd. The shares were sold at an average price of $539.23, for a total value of $968,996.31. Following the completion of the sale, the insider owned 83,485 shares of the company’s stock, valued at $45,017,616.55. This represents a 2.11% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Patrick W. Smith sold 10,000 shares of the firm’s stock in a transaction on Monday, December 8th. The shares were sold at an average price of $551.92, for a total transaction of $5,519,200.00. Following the completion of the transaction, the chief executive officer directly owned 3,110,997 shares in the company, valued at approximately $1,717,021,464.24. This represents a 0.32% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 60,540 shares of company stock valued at $34,684,738 over the last quarter. 4.40% of the stock is owned by insiders.

Axon Enterprise Price Performance

AXON stock opened at $483.58 on Friday. The company has a market cap of $38.16 billion, a PE ratio of 153.03, a price-to-earnings-growth ratio of 15.35 and a beta of 1.41. The company has a current ratio of 3.12, a quick ratio of 2.89 and a debt-to-equity ratio of 0.57. The stock has a 50-day moving average price of $578.34 and a two-hundred day moving average price of $669.10. Axon Enterprise, Inc has a 12-month low of $469.24 and a 12-month high of $885.91.

Axon Enterprise (NASDAQ:AXON) last released its quarterly earnings data on Wednesday, November 5th. The biotechnology company reported $1.17 EPS for the quarter, missing analysts’ consensus estimates of $1.63 by ($0.46). Axon Enterprise had a return on equity of 4.29% and a net margin of 10.05%.The firm had revenue of $710.64 million during the quarter, compared to analysts’ expectations of $704.83 million. During the same quarter last year, the business earned $1.45 earnings per share. The business’s revenue for the quarter was up 30.6% compared to the same quarter last year. As a group, research analysts predict that Axon Enterprise, Inc will post 5.8 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the stock. UBS Group reduced their price target on shares of Axon Enterprise from $840.00 to $610.00 and set a “neutral” rating on the stock in a report on Wednesday, November 5th. Northcoast Research raised Axon Enterprise from a “neutral” rating to a “buy” rating and set a $742.00 target price on the stock in a research note on Tuesday, January 6th. Piper Sandler lowered their target price on Axon Enterprise from $893.00 to $753.00 and set an “overweight” rating on the stock in a report on Wednesday, November 5th. Wall Street Zen cut Axon Enterprise from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. Finally, Barclays dropped their price objective on Axon Enterprise from $861.00 to $702.00 and set an “overweight” rating for the company in a research report on Thursday, November 6th. Fourteen research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $805.71.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.